Sep. 2, 2021—When a drug or combination of drugs causes different responses in different people, genetic variation is often at play. Pharmacogenomics, through discovery of genetic risk and use of clinical genotyping, aims to reduce trial-and-error approaches to drug prescribing.
Apr. 30, 2020—A new clinic opening at Vanderbilt University Medical Center will help doctors and patients choose the best drugs for their medical conditions based on the patients’ unique genetic makeup.
Oct. 1, 2015—La Jolla Pharmaceutical Co. and Vanderbilt University have signed a research and license agreement covering Vanderbilt’s research program and intellectual property rights related to compounds that block bone morphogenetic protein (BMP) type-I receptors. The compounds have therapeutic potential in a broad range of diseases, including rare genetic disorders.
Apr. 23, 2015—Preemptive genotyping: It sounds like a surprise attack, and it is.
Oct. 24, 2013—With the aid of a two-year, $487,000 National Leadership Grant from the Institute of Museum and Library Services (IMLS), a Vanderbilt research team will develop a reusable model to promote better patient engagement with the health care team through delivery of consumer-friendly pharmacogenetic information.
Oct. 17, 2013—A research team led by Josh Peterson, M.D., MPH, assistant professor of Biomedical Informatics and Medicine, and John Graves, Ph.D., assistant professor of Preventive Medicine, will study the cost-effectiveness of testing patients’ risk of adverse gene-drug interactions.